Metanx^® Resources

MetanxPRO Nerve Health™ is a medical food specially formulated to meet the distinctive nutritional requirements for endothelial dysfunction in the clinical dietary management of peripheral neuropathy and associated diabetic ulceration. Use under medical supervision.

Metanx FC™ is a medical food for use under medical supervision for the clinical dietary management of peripheral neuropathy and associated diabetic ulcer and are specially formulated to meet the distinct nutritional requirements for these conditions.

* Metanx FC™ and MetanxPRO Nerve Health™ contain no unnecessary additives or major allergens (no fish, shellfish, wheat, eggs, milk, tree nuts, peanuts, soy, or sesame).

† Clinical studies on a formulation of METANX—which contained the same levels of L-methylfolate, pyridoxal 5'-phosphate, and methylcobalamin as in MetanxPRO Nerve Health™—demonstrated sustained improvements in pain, sensory symptoms, and quality of life in patients with diabetic peripheral neuropathy (DPN, the most common form of peripheral neuropathy).

^§Names have been changed and images don’t portray actual consumers and are for illustration purposes only.

1. Youle M, et al. HIV Medicine. 2007;8(4):241-250. 2. Scarpini E, et al. Journal of the Peripheral Nervous System. 1997;2(3):250-252. 3. Maestri A, et al. Tumori Journal. 2005;91(2):135-138. 4. Trippe BS, et al. Current Medical Research and Opinion. 2016;32(2):219-227. 5. Walker MJ Jr. Reviews in Neurological Diseases. 2010;7(4):132-139. 6. Fonseca VA, et al. American Journal of Medicine. 2013;126(2):141-149. 7. Jacobs AM, et al. Reviews in Neurological Diseases. 2011;8(1-2):39-47. 8. Jacobs AM, et al. Journal of Diabetes Mellitus. 2013;3(3):134-138. 9. Christofides EA and Valentine V. Endocrine Practice. 2023;29(8):663-669. 10. National Institute of Neurological Disorders and Stroke. Peripheral neuropathy. https://www.ninds.nih.gov/health-information/disorders/peripheral-neuropathy. 11. Cashman CR and Höke A. Neuroscience Letters. 2015;596:33-50. 12. Maiuolo J, et al. International Journal of Molecular Sciences. 2019;20(12):3022. 13. Tiwari A, et al. Cureus. 2023;15(10):e47771. 14. Yang M, et al. Pain Medicine. 2015;16(11):2075-2083. 15. Julian T, et al. Nutrients. 2020;12(8):2221. 16. Traina G. Frontiers in Bioscience-Landmark. 2016;21(7):1314-1329. 17. Chiechio S, et al. Molecular Pharmacology. 2002;61(5):989-996. 18. Quéré I, et al. The Lancet. 2002;359(9308):747-752. 19. Austin RC, et al. Cell Death and Differentiation. 2004;11 Suppl 1:S56-S64. 20. Moretti R and Caruso P. International Journal of Molecular Sciences. 2019;20(1):231. 21. Liwinski T and Lang UE. Nutrients. 2023;15(17):3859. 22. Calderón-Ospina CA, et al. CNS Neuroscience & Therapeutics. 2020;26(1):5-13. 23. Alghamdi M, et al. Clinical Genetics. 2021;99(1):99-110. 24. Merigliano C, et al. Scientific Reports. 2018;8(1):11432. 25. Ankar A, et al. Vitamin B12 deficiency. In: StatPearls [Internet]. Updated September 2024. https://www.ncbi.nlm.nih.gov/books/NBK441923/. Accessed June 06, 2025. 26. National Institutes of Health Office of Dietary Supplements. Carnitine. 27. Teleanu RI, et al. International Journal of Molecular Sciences. 2022;23(11):5954. 28. Han Q, et al. Cell Metabolism. 2020;31(3):623-641. 29. Liu J, et al. PNAS. 2002;99(4):2356-2361. 30. Onofrj M, et al. Expert Review of Neurotherapeutics. 2013;13(8):925-936. 31. van de Lagemaat EE, et al. Nutrients. 2019;11(2):482. 32. Kumrungsee T, et al. Frontiers in Nutrition. 2020;29(7):562051. 33. Nakamura S, et al. Nephrology Dialysis Transplantation. 2007;22(8):2165-2174. 34. Peters TJ, et al. Alcohol and Alcoholism. 2006;41(6):636-642. 35. Antoniades C, et al. Circulation. 2006;114(11):1193-1201. 36. Raghubeer S and Matsha TE. Nutrients. 2021;13(12):4562. 37. Dahal S and Devi NK. Genes associated with one-carbon metabolic pathway and depression. In: Handbook of the Biology and Pathology of Mental Disorders. 2024; Springer. https://doi.org/10.1007/978-3-031-32035- 4_32-1. 38. Kaye AD, et al. Advances in Therapy. 2020;37(10):4149-4164. 39. Cheng CH, et al. BioMed Research International. 2013;2013:572081. 40. Pokushalov E, et al. Nutrients. 2024;16(11):1550. 41. Chambers JC, et al. Circulation. 2000;102(20):2479-2483. 42. Han X, et al. BMC Cancer. 2017;17(1):40. 43. Goldberg H, et al. Journal of Pain Research. 2017;10:397-404. 44. Huang ZF, et al. Journal of Back and Musculoskeletal Rehabilitation. 2019;32(2):329-337. 45. Zhang M, et al. Neural Plasticity. 2013;2013:424651. 46. Fenn-Moltu S, et al. Brain Behaviour and Immunity. 2023;111:343-351 47. Carlton SM, et al. Brain Research. 1999;820(1-2):63-70 48. Willems FF. British Journal of Pharmacology. 2004;141(5):825-830. 105. Walker MJ Jr. Reviews in Neurological Diseases. 2010;7(4):132-139. 49. METANX®. Package insert. Alfasigma USA, Inc. 50. Sadowski A, et al. Alcoholic Neuropathy. In: StatPearls [Internet]. StatPearls Publishing. Updated December 2022. https://www.ncbi.nlm.nih.gov/books/NBK499856/. Accessed January 10, 2025. 51. Sommer C, et al. Deutsches Ärzteblatt International. 2018;115(6):83-90. 52. Bae EH, et al. Neurotherapeutics. 2021;18(4):2384-2396. 53. Lu HJ, et al. Frontiers in Pharmacology. 2021;12:653852. 54. Bou Ghanem A, et al. Frontiers in Aging Neuroscience. 2024;15:1322419. 55. Lionaki E, et al. Cells. 2022;11(2):214. 56. Hasan SS, et al. Trends in Cell Biology. 2021;31(1):37-49. 57. Yowtak J, et al. Pain. 2011;152(4):844-852. 58. Zhang W, et al. Signal Transduction and Targeted Therapy. 2023;8(1):267. 59. Zhao XY, et al. Frontiers in Neuroscience. 2019;13:30. 60. Seungyoon BY, et al. Journal of Molecular Biology. 2018;430(21):3922-3941. 61. Mayo Clinic. Myocardial ischemia. https://www.mayoclinic.org/diseases-conditions/myocardial-ischemia/symptoms-causes/syc-20375417. Accessed June 06, 2025. 62. Sima A, et al. Diabetes Care. 2005;28(1):96-101.